Inhaled aztreonam lysine: an evidence-based review
- 28 August 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 14 (15) , 2115-2124
Abstract
Introduction: Chronic airway infection in cystic fibrosis (CF) is linked with progressive loss of pulmonary function and is the primary cause of mortality. Treatment regimens have generally focused on the use of chronic antibiotic therapy to target Pseudomonas aeruginosa (PA), a major pathogen associated with a decline in FEV1%. Specifically, inhaled antibiotic therapy provides high antibiotic sputum concentrations and decreases bacterial burden. Areas covered: This article describes the pharmacology, pharmacodynamics/pharmacokinetics, clinical efficacy, microbiology and safety of aztreonam lysine (AZLI, Cayston), an inhaled antibiotic indicated for use in CF patients with PA. Articles were identified using MEDLINE (1966 – June 13, 2013) and EMBASE (1947 – June 13, 2013). Abstracts from the annual meeting (2011 – 2012) of the North American Cystic Fibrosis Conference were searched to identify additional publications. Expert opinion: AZLI is an additional product that can be used in the management of CF and will likely play a major role in the suppression of PA. Clinical trials have demonstrated improvements in pulmonary function and patient reported symptoms. AZLI may therefore be used as an alternative to traditional inhaled antibiotics in patients with moderate-to-severe CF and PA colonization. Further investigation is warranted into use of AZLI in mild lung disease and for PA eradication.Keywords
This publication has 27 references indexed in Scilit:
- Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trialJournal of Cystic Fibrosis, 2013
- Aztreonam lysine for inhalation: New formulation of an old antibioticAmerican Journal of Health-System Pharmacy, 2012
- Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based reviewCore Evidence, 2011
- Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosisBMC Medicine, 2011
- In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal InfectionAntimicrobial Agents and Chemotherapy, 2009
- Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic FibrosisChest, 2009
- Cystic fibrosisThe Lancet, 2009
- Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Effect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjectsThorax, 1998